MODERNA INC (MRNA) Fundamental Analysis & Valuation

NASDAQ:MRNA • US60770K1079

52.52 USD
-1.31 (-2.43%)
At close: Mar 6, 2026
54.1601 USD
+1.64 (+3.12%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MRNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MRNA. MRNA was compared to 519 industry peers in the Biotechnology industry. While MRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, MRNA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. MRNA Profitability Analysis

1.1 Basic Checks

  • In the past year MRNA has reported negative net income.
  • MRNA had a negative operating cash flow in the past year.
  • In multiple years MRNA reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MRNA reported negative operating cash flow in multiple years.
MRNA Yearly Net Income VS EBIT VS OCF VS FCFMRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

1.2 Ratios

  • With a decent Return On Assets value of -22.87%, MRNA is doing good in the industry, outperforming 73.08% of the companies in the same industry.
  • MRNA has a Return On Equity of -32.62%. This is in the better half of the industry: MRNA outperforms 73.27% of its industry peers.
Industry RankSector Rank
ROA -22.87%
ROE -32.62%
ROIC N/A
ROA(3y)-24.55%
ROA(5y)1.63%
ROE(3y)-33.11%
ROE(5y)6.13%
ROIC(3y)N/A
ROIC(5y)N/A
MRNA Yearly ROA, ROE, ROICMRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 80

1.3 Margins

  • MRNA has a Gross Margin of 70.32%. This is amongst the best in the industry. MRNA outperforms 81.73% of its industry peers.
  • MRNA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.73%
GM growth 5Y-6.61%
MRNA Yearly Profit, Operating, Gross MarginsMRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MRNA Health Analysis

2.1 Basic Checks

  • MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MRNA has more shares outstanding
  • MRNA has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MRNA is higher compared to a year ago.
MRNA Yearly Shares OutstandingMRNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
MRNA Yearly Total Debt VS Total AssetsMRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • MRNA has an Altman-Z score of 4.10. This indicates that MRNA is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of MRNA (4.10) is better than 70.38% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that MRNA is not too dependend on debt financing.
  • MRNA has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: MRNA underperforms 60.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 4.1
ROIC/WACCN/A
WACC8.68%
MRNA Yearly LT Debt VS Equity VS FCFMRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 3.29 indicates that MRNA has no problem at all paying its short term obligations.
  • MRNA has a Current ratio of 3.29. This is in the lower half of the industry: MRNA underperforms 60.77% of its industry peers.
  • A Quick Ratio of 3.22 indicates that MRNA has no problem at all paying its short term obligations.
  • MRNA's Quick ratio of 3.22 is on the low side compared to the rest of the industry. MRNA is outperformed by 60.19% of its industry peers.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.22
MRNA Yearly Current Assets VS Current LiabilitesMRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MRNA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.66% over the past year.
  • MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.93%.
  • MRNA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.34% yearly.
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
Revenue 1Y (TTM)-39.93%
Revenue growth 3Y-53.44%
Revenue growth 5Y19.34%
Sales Q2Q%-29.81%

3.2 Future

  • Based on estimates for the next years, MRNA will show a very strong growth in Earnings Per Share. The EPS will grow by 21.01% on average per year.
  • MRNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.07% yearly.
EPS Next Y2.17%
EPS Next 2Y13.98%
EPS Next 3Y16.77%
EPS Next 5Y21.01%
Revenue Next Year7.32%
Revenue Next 2Y9.8%
Revenue Next 3Y17.2%
Revenue Next 5Y29.07%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRNA Yearly Revenue VS EstimatesMRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
MRNA Yearly EPS VS EstimatesMRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 -10 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRNA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRNA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRNA Price Earnings VS Forward Price EarningsMRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRNA Per share dataMRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • MRNA's earnings are expected to grow with 16.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.98%
EPS Next 3Y16.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRNA Dividend Analysis

5.1 Amount

  • No dividends for MRNA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRNA Fundamentals: All Metrics, Ratios and Statistics

MODERNA INC

NASDAQ:MRNA (3/6/2026, 8:00:02 PM)

After market: 54.1601 +1.64 (+3.12%)

52.52

-1.31 (-2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13
Earnings (Next)04-29
Inst Owners71.72%
Inst Owner Change8.09%
Ins Owners2.73%
Ins Owner Change1.53%
Market Cap20.52B
Revenue(TTM)1.94B
Net Income(TTM)-2.82B
Analysts56
Price Target42.49 (-19.1%)
Short Float %19.72%
Short Ratio5.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.99%
Min EPS beat(2)21.72%
Max EPS beat(2)76.27%
EPS beat(4)4
Avg EPS beat(4)37.2%
Min EPS beat(4)21.22%
Max EPS beat(4)76.27%
EPS beat(8)7
Avg EPS beat(8)32.95%
EPS beat(12)10
Avg EPS beat(12)13.09%
EPS beat(16)12
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)9.26%
Min Revenue beat(2)6.17%
Max Revenue beat(2)12.36%
Revenue beat(4)3
Avg Revenue beat(4)10.37%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)23.26%
Revenue beat(8)7
Avg Revenue beat(8)29.33%
Revenue beat(12)11
Avg Revenue beat(12)27.78%
Revenue beat(16)13
Avg Revenue beat(16)23.1%
PT rev (1m)13.02%
PT rev (3m)2.29%
EPS NQ rev (1m)9.04%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)1%
EPS NY rev (3m)10.12%
Revenue NQ rev (1m)-9.95%
Revenue NQ rev (3m)6.41%
Revenue NY rev (1m)1.57%
Revenue NY rev (3m)-3.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.55
P/FCF N/A
P/OCF N/A
P/B 2.37
P/tB 2.4
EV/EBITDA N/A
EPS(TTM)-7.27
EYN/A
EPS(NY)-7.11
Fwd EYN/A
FCF(TTM)-5.31
FCFYN/A
OCF(TTM)-4.79
OCFYN/A
SpS4.98
BVpS22.14
TBVpS21.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.87%
ROE -32.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.32%
FCFM N/A
ROA(3y)-24.55%
ROA(5y)1.63%
ROE(3y)-33.11%
ROE(5y)6.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.73%
GM growth 5Y-6.61%
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.95%
Cap/Sales 10.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.22
Altman-Z 4.1
F-Score3
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)254.63%
Cap/Depr(5y)200.25%
Cap/Sales(3y)17.73%
Cap/Sales(5y)11.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.49%
EPS Next Y2.17%
EPS Next 2Y13.98%
EPS Next 3Y16.77%
EPS Next 5Y21.01%
Revenue 1Y (TTM)-39.93%
Revenue growth 3Y-53.44%
Revenue growth 5Y19.34%
Sales Q2Q%-29.81%
Revenue Next Year7.32%
Revenue Next 2Y9.8%
Revenue Next 3Y17.2%
Revenue Next 5Y29.07%
EBIT growth 1Y20.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.09%
EBIT Next 3Y20.09%
EBIT Next 5Y20.41%
FCF growth 1Y48.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.65%
OCF growth 3YN/A
OCF growth 5YN/A

MODERNA INC / MRNA FAQ

What is the fundamental rating for MRNA stock?

ChartMill assigns a fundamental rating of 3 / 10 to MRNA.


What is the valuation status for MRNA stock?

ChartMill assigns a valuation rating of 0 / 10 to MODERNA INC (MRNA). This can be considered as Overvalued.


How profitable is MODERNA INC (MRNA) stock?

MODERNA INC (MRNA) has a profitability rating of 2 / 10.